AbbVie IncNYSE: ABBV
Health Care · Biotechnology
$207.05
-2.02%
Vol: 11.2M
Research Digest
Friday, May 1, 2026
AbbVie Q1 2026 revenues beat at $15.0B (+12.4% YoY); Skyrizi up 30.9%, neuroscience up 26%; raised FY guidance with $1.4B Durham facility investment
AbbVie reported Q1 2026 revenues of $15.002 billion (up 12.4% reported, 10.3% operational basis). Immunology revenues hit $7.290B (+16.4%), with Skyrizi driving growth at $4.483B (+30.9%). Neuroscience segment fastest growth at 26% YoY. Company announced positive Phase 1 results for weight-management candidate ABBV-295 and FDA submission for Upadacitinib in alopecia areata. $1.4B investment in Durham NC manufacturing campus announced. Full-year guidance raised.
Previous Market Intelligence
13 daysApr 30AbbVie surges 6.97% week on robust Q1 beat; raises FY guidance as Skyrizi and Rinvoq drive immunology strength offsetting Humira declinePositive▶
ABBV reported strong Q1 2026 with $15B revenue (+12.4% YoY), EPS $2.65 (beat guidance by $0.07). Raised FY revenue guidance to ~$67.3B and FY EPS guidance +$0.12 to $14.08-14.28. Skyrizi + Rinvoq generated $6.6B+ sales, offsetting Humira revenue decline. Botox Cosmetic up 20.2% to $668M. BofA upgraded to Buy; Canaccord raised PT. FDA submissions pending for Upadacitinib alopecia areata and Skyrizi Crohn's induction. Stock up 6.97% weekly to $212.96. Risk: competitive biosimilar/generic pressure, clinical trial setbacks, patent cliffs.
Apr 29AbbVie reports Q1 2026 earnings beat: revenue $15B (+12.4%), adjusted EPS $2.65 (+7.7%), raises FY2026 guidance to $14.08-$14.28Positive▶
AbbVie crushed Q1 expectations on April 29: revenue $15B (+12.4% reported), adjusted EPS $2.65 vs. guidance, beating by $0.07. Immunology portfolio surged 16.4% to $7.29B. Skyrizi revenue $4.48B (+30.9% YoY), Rinvoq $2.12B (+23.3% YoY). Company raised FY2026 adjusted EPS guidance from $13.96-$14.16 to $14.08-$14.28 (including $0.41 IPR&D headwind). FDA approved supplemental sNDA for Venclexta/acalabrutinib combination for untreated CLL. $100B U.S. investment commitment includes $1.4B pharma campus in NC. Despite strong results, stock fell 4.25% pre-market to $189.28.
Apr 16AbbVie signs $745M deal with Haisco Pharma for novel pain treatments; lowers 2026 guidance amid clinical progress in ovarian cancer pipelineMixed▶
AbbVie announced an exclusive licensing agreement with Haisco Pharmaceutical Group, providing $30 million upfront and up to $715 million in milestones for novel pain treatment candidates outside Greater China, strengthening its neuroscience focus. The company presented positive Phase II data for Elahere in platinum-sensitive ovarian cancer with a 62.7% objective response rate at the SGO 2026 conference. However, AbbVie has faced headwinds including the termination of its dermal and soft tissue filler partnership with CollPlant and a lowering of 2026 earnings guidance. The stock is down 2.20% today amid these mixed developments.
Apr 15AbbVie showcases positive Phase 2 data for Elahere in ovarian cancer at SGO 2026; stock flat at $208.51Neutral▶
AbbVie presented positive Phase II data for Elahere with 62.7% objective response rate in platinum-sensitive ovarian cancer. Company announced exclusive licensing deal with Haisco for pain treatment candidates worth $30M upfront plus up to $715M in milestones. Stock trades flat at $208.51 with upcoming FQ1 2026 earnings.
Apr 14AbbVie Phase 2 ovarian cancer data shows 62.7% response rate; FY2026 EPS guidance below consensusNegative▶
Phase 2 data for mirvetuximab in ovarian cancer showed 62.7% response rate. FY2026 EPS guidance $13.96-$14.16 below consensus $14.56. Q1 results April 29. Stock slid 2.20%.
Apr 13AbbVie lowers Q1 2026 EPS guidance to $2.56-$2.60 vs $3.01 consensus; Q1 earnings April 29Negative▶
AbbVie issued lower-than-consensus Q1 2026 EPS guidance of $2.56-$2.60 (vs $3.01 consensus) and FY2026 guidance of $13.96-$14.16. Company announced April 29 earnings report. Humira now available on TrumpRx at 86% discount. Phase 2 trial data for mirvetuximab soravtansine-gynx in ovarian cancer showed 62.7% objective response rate. Dividend $1.73 per share on May 15.
Apr 10AbbVie launches Humira on TrumpRx at 86% discount while preparing robust Q1 results April 29.Positive▶
AbbVie announced Humira availability on TrumpRx platform with 86% discount. Q1 2026 earnings April 29 expected to deliver robust performance with revenues ~$14.7B (up 8% YoY). Skyrizi and Rinvoq driving growth following Humira's loss of exclusivity. Stock at $210.59 with analyst consensus Buy and $247.74 target. Company made $100B U.S. investment pledge.
Apr 9AbbVie rises on dermatology data and low-cost Humira launchPositive▶
AbbVie stock gained 2.42% as investors reacted positively to new dermatology clinical data and the launch of an 86% lower-cost Humira following a White House pricing deal. The company pledged $100 billion to US R&D and manufacturing over ten years while also receiving expanded Skyrizi indications. Recent AAD meeting presentations highlighted long-term safety data for key franchises. Cantor Fitzgerald maintained overweight rating while lowering price target to $240.
Apr 8AbbVie lowers 2026 EPS guidance to $13.96-$14.16 due to $744M acquisition expenses.Mixed▶
AbbVie issued preliminary financial update reducing 2026 adjusted diluted EPS guidance to $13.96-$14.16, below $14.52 consensus, citing $744M in pre-tax expenses from acquired in-process R&D. Scotiabank assigned Buy rating. Company expects Skyrizi and Rinvoq combined sales to exceed $31 billion by 2026. Q1 earnings April 29.
Apr 7AbbVie Q1 2026 earnings due April 29 as Skyrizi and Rinvoq dermatology data support immunology growth.Neutral▶
AbbVie detailed clinical and real-world dermatology data for Skyrizi and Rinvoq at the American Academy of Dermatology meeting in late March. The company faces pressure from potential U.S. drug tariffs and stock has declined 9.24% over the past month. Analysts project Q1 EPS at $3.01 (up 22.36% YoY) and revenue of $14.78 billion (up 10.74% YoY). The average Buy rating from 20 analysts targets $247.74 (up 15.37%). ABBV trades at $206.69, down 1.03% on the day.
Apr 6AbbVie lowers 2026 EPS guidance on $744M IPR&D charge.Negative▶
AbbVie revised 2026 EPS guidance lower with $744M IPR&D charge. Q1 2026 adjusted EPS guidance lowered to $2.56-$2.60; full-year to $13.96-$14.16 from $14.37-$14.57. Q1 earnings April 29. Tariff concerns on US drug imports persist.
Apr 3AbbVie to report Q1 2026 earnings April 29 with expected 22.4% EPS growth; dermatology research shows strong clinical efficacy data.Positive▶
AbbVie announced new dermatology research at the American Academy of Dermatology Annual Meeting highlighting clinical evidence for key drugs risankizumab and upadacitinib. The company is launching its fourth annual CoolMonth promotion in April. Q1 2026 earnings are scheduled for April 29 before market open, with analysts expecting EPS of $3.01 per share, up 22.4% from $2.46 year-ago. The consensus rating is Moderate Buy with an average price target of $249.82, implying 16.2% upside.
Apr 1AbbVie presents 24 dermatology studies at AAD 2026 conference with Phase 3 alopecia and vitiligo data supporting clinical pipeline strength.Positive▶
AbbVie showcased new dermatology research at the 2026 American Academy of Dermatology Annual Meeting, including five-year psoriatic arthritis outcomes and Phase 3 data for risankizumab and upadacitinib in alopecia areata and vitiligo. The company also announced positive Phase 1 results for ABBV-295, a long-acting amylin analog. Stock moved up 3.26% on March 31 and continues to benefit from strong quarterly earnings announced in February with $2.71 EPS beating consensus. Dividend of $1.73 with ex-date of April 15, 2026. Next earnings report scheduled for April 24, 2026.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABBVABBVIE | $207.05 | -2.02% | +2.2% | 13.1x | — | $373.8B |
| AMGNAMGEN | $330.27 | -4.62% | +1.1% | 14.8x | 0.47 | $186.7B |
| GILDGILEAD | $131.80 | +0.73% | -6.6% | 13.6x | 0.40 | $162.4B |
| VRTXVERTEX | $425.02 | -0.55% | -1.6% | 19.6x | 0.37 | $108.7B |
| REGNREGENERON | $702.19 | -0.69% | -7.3% | 13.0x | 0.40 | $74.1B |
| BIIBBIOGEN | $187.16 | -1.12% | +9.8% | 11.9x | 0.16 | $27.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.